

Shuichi Kishimoto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1946012/publications.pdf>

Version: 2024-02-01

15
papers

332
citations

1040056

9
h-index

1058476

14
g-index

15
all docs

15
docs citations

15
times ranked

293
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | The Involvement of Pregnane X Receptor-regulated Pathways in the Antitumor Activity of Cisplatin. <i>Anticancer Research</i> , 2019, 39, 3601-3608. | 1.1 | 6 |
| 2 | Comparison of Pregnane X Receptor Antagonists for Enhancing the Antitumor Effect of Cisplatin. <i>Anticancer Research</i> , 2019, 39, 4749-4755. | 1.1 | 3 |
| 3 | Angiographic Evaluation of Vascular Damage in Rat Liver After Administration of Epirubicin or Miriplatin. <i>Anticancer Research</i> , 2018, 38, 247-251. | 1.1 | 3 |
| 4 | Changes in the Expression of Various Transporters as Influencing Factors of Resistance to Cisplatin. , 2017, 37, 5477-5484. | | 3 |
| 5 | Intracellular uptake of an antitumor-active azole-bridged dinuclear platinum(II) complex in cisplatin-resistant tumor cells. <i>BioMetals</i> , 2016, 29, 1075-1083. | 4.1 | 6 |
| 6 | Effects of insulin on CYP3A activity and nicardipine disposition in streptozotocin-induced diabetic rats. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 62, 883-889. | 2.4 | 9 |
| 7 | Role of Na ⁺ , K ⁺ -ATPase $\hat{I}\pm 1$ subunit in the intracellular accumulation of cisplatin. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 84-90. | 2.3 | 37 |
| 8 | Continuous Exposure to Low-Dose Cisplatin and Apoptosis. <i>Biological and Pharmaceutical Bulletin</i> , 2005, 28, 1954-1957. | 1.4 | 16 |
| 9 | Relation between Intracellular Accumulation and Cytotoxic Activity of cis-[[((1R,2R)-1,2-Cyclohexanediamine-N,N')bis(myristato)]platinum(II) Suspended in Lipiodol. <i>Biological and Pharmaceutical Bulletin</i> , 2003, 26, 683-686. | 1.4 | 16 |
| 10 | Antitumor Effects of a Novel Lipophilic Platinum Complex (SM-11355) against a Slowly-Growing Rat Hepatic Tumor after Intra-Hepatic Arterial Administration.. <i>Biological and Pharmaceutical Bulletin</i> , 2000, 23, 344-348. | 1.4 | 27 |
| 11 | In Vitro Release of SM-11355, cis[[((1R,2R)-1,2-Cyclohexanediamine-N,N')bis(myristato)] Platinum(II) Suspended in Lipiodol.. <i>Biological and Pharmaceutical Bulletin</i> , 2000, 23, 637-640. | 1.4 | 27 |
| 12 | In Vitro Cytotoxicity of cis[[((1R,2R)-1,2-Cyclohexanediamine-N,N')bis(myristato)] Platinum(II) Suspended in Lipiodol in Rat Hepatoma AH-109A Cells and Human Tumor Cell Lines.. <i>Biological and Pharmaceutical Bulletin</i> , 2000, 23, 487-491. | 1.4 | 6 |
| 13 | In vitro Antitumor Activity, Intracellular Accumulation, and DNA Adduct Formation of cis-[[((1R,2R)-1,2-Cyclohexanediamine-N,N')bis(myristato)]platinum(II) Suspended in Lipiodol. <i>Cancer Research</i> , 2000, 60, 1074-1079. | 1.7 | 10 |
| 14 | Cytotoxicity of cis-[[((1R,2R)-1,2-Cyclohexanediamine-N,N')bis(myristato)]-platinum (II) Suspended in Lipiodol in a Newly Established Cisplatin-resistant Rat Hepatoma Cell Line. <i>Japanese Journal of Cancer Research</i> , 2000, 91, 1326-1332. | 1.7 | 30 |
| 15 | Hepatic arterial injection chemotherapy with cisplatin suspended in an oily lymphographic agent for hepatocellular carcinoma. <i>Cancer</i> , 1989, 64, 1586-1594. | 4.1 | 133 |